News

The Austrian biotech company is partnering with the Coalition for Epidemic Preparedness Innovations (CEPI) for the development of the MV-LASV Lassa fever vaccine candidate. The phase 1 trial

Based on these results the compound has been advanced to Phase I clinical testing alone and in combination with trametinib in patients with different types of advanced solid

The data is being presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston,USA. Within its PDD platform, Femtogenix has developed a lower potency DNA mono-alkylator

NASH is a severe form of non-alcoholic fatty liver disease (NAFLD), which results due to the accumulation of excess fat in the liver. The disease, which is associated

The UK-based pharma company said that it has started dosing of patients in the phase 3 programme, which will test gepotidacin in two studies – EAGLE-1 and EAGLE-2.

Bavencio, which is a human anti-programmed death ligand-1 (PD-L1) antibody, has been demonstrated in preclinical models to engage both the adaptive and innate immune functions. The combined therapy

“We are excited about the opportunity to partner with Glympse Bio to help inform our NASH development program,” said Mani Subramanian, MD, PhD Senior Vice President, Liver Diseases,

The trial met a primary endpoint by showing a statistically significant and clinically meaningful improvement in the final PFS analysis in patients treated with the combination of Imfinzi

“The MAHOGANY study for patients with gastric or gastroesophageal junction cancer is designed to support registration of margetuximab and is a part of our strategy to advance margetuximab